Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Consejo Superior de Investigaciones Científicas has 2 pending office actions currently under review. These actions are distributed among 2 distinct examiners, meaning each pending case is being handled by a different individual. Raghu, Ganapathiram is the busiest examiner for the portfolio, with 1 pending office action. The presence of the distinct examiners for the pending office actions shows a lack of examiner concentration in the current workload. This distribution requires the company to manage multiple examiner relationships simultaneously and involves 0 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
| WOOLWINE, SAMUEL C | 1 | 61.0% | +20.4% |
| LI, BAO Q | 1 | 75.4% | +26.8% |
| GODDARD, LAURA B | 1 | 50.9% | +13.5% |
| MCCORMACK, ERIN KATHLEEN | 1 | 8.6% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 15d overdue |
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | — |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | — |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 15d overdue |
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | — |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | — |
| 18713083 | CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES | LI, BAO Q | — |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18862189 | ANTIVIRAL COMPOUNDS AND COMPOSITIONS THEREFROM | BURKETT, DANIEL JOHN | — | §102§112 | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18723155 | DETECTION OF TELOMERE FUSION EVENTS | WOOLWINE, SAMUEL C | — | §101§102§103§112 | Non-Final OA | — | Pending | Jun 21, 2024 |
| 18713083 | CORONAVIRUS DERIVED RNA REPLICONS AND THEIR USE AS VACCINES | LI, BAO Q | — | §112 | Non-Final OA | — | Pending | May 23, 2024 |
| 18553464 | ANTIBODY AND USE THEREOF FOR THE TREATMENT OF CANCER | GODDARD, LAURA B | 1642 | §101§102 | Final Rejection | — | Pending | Sep 29, 2023 |
| 17790029 | PROCEDURE AND DEVICE TO PRODUCE A REFLEX TEAR SECRETION AND A KIT FOR THE MEASUREMENT OF THE MAGNITUDE OF THE EVOKED TEAR FLOW | MCCORMACK, ERIN KATHLEEN | 3791 | §103 | Final Rejection | 15d overdue | Pending | Jun 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial